Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3731) 3731
Book Review (422) 422
Publication (245) 245
Newsletter (196) 196
Magazine Article (15) 15
Conference Proceeding (14) 14
Book Chapter (2) 2
Paper (2) 2
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3040) 3040
pravastatin (2747) 2747
humans (2254) 2254
male (1710) 1710
pharmacology & pharmacy (1628) 1628
female (1211) 1211
animals (1137) 1137
statins (1078) 1078
pravastatin - pharmacology (1033) 1033
simvastatin (1001) 1001
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (935) 935
middle aged (908) 908
cholesterol (760) 760
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (679) 679
atorvastatin (673) 673
adult (662) 662
aged (660) 660
rats (552) 552
pravastatin - therapeutic use (522) 522
hypercholesterolemia (503) 503
prevention (439) 439
lovastatin (435) 435
anticholesteremic agents - pharmacology (426) 426
cardiac & cardiovascular systems (421) 421
hypercholesterolemia - drug therapy (418) 418
atherosclerosis (401) 401
cholesterol - blood (395) 395
atorvastatin calcium (364) 364
coronary-heart-disease (349) 349
anticholesteremic agents - therapeutic use (344) 344
risk (339) 339
cholesterol, ldl - blood (329) 329
simvastatin - pharmacology (327) 327
antilipemic agents (323) 323
peripheral vascular disease (310) 310
coa reductase inhibitors (309) 309
mice (307) 307
risk factors (303) 303
dose-response relationship, drug (298) 298
heptanoic acids - pharmacology (293) 293
drug interactions (285) 285
abridged index medicus (279) 279
research (274) 274
treatment outcome (269) 269
pharmacokinetics (263) 263
cells, cultured (261) 261
hmg-coa reductase (261) 261
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (261) 261
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (257) 257
pyrroles - pharmacology (255) 255
therapy (254) 254
lipids (252) 252
analysis (249) 249
myocardial-infarction (249) 249
statin (247) 247
disease (243) 243
lovastatin - pharmacology (242) 242
drug therapy (234) 234
fluvastatin (226) 226
rosuvastatin (225) 225
pravastatin - administration & dosage (221) 221
hydroxymethylglutaryl-coa reductase inhibitors (218) 218
medicine & public health (215) 215
double-blind method (213) 213
time factors (211) 211
drugs (207) 207
events (205) 205
expression (199) 199
inflammation (199) 199
lipids - blood (197) 197
rats, sprague-dawley (197) 197
men (194) 194
triglycerides - blood (194) 194
simvastatin - therapeutic use (193) 193
biochemistry & molecular biology (189) 189
metabolism (189) 189
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (187) 187
hypercholesterolemia - blood (187) 187
coenzyme-a reductase (182) 182
efficacy (181) 181
liver - metabolism (181) 181
pravastatin - pharmacokinetics (180) 180
heptanoic acids - therapeutic use (178) 178
pharmacology/toxicology (177) 177
pyrroles - therapeutic use (167) 167
safety (164) 164
nitric-oxide synthase (163) 163
medicine, research & experimental (159) 159
hyperlipidemias - drug therapy (157) 157
pharmacology (157) 157
c-reactive protein (156) 156
coronary heart disease (156) 156
mortality (155) 155
rosuvastatin calcium (155) 155
cardiovascular disease (150) 150
in-vitro (150) 150
cardiovascular agents (149) 149
care and treatment (149) 149
cholesterol, hdl - blood (146) 146
disease models, animal (146) 146
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3803) 3803
Japanese (54) 54
French (23) 23
Chinese (19) 19
Spanish (14) 14
German (11) 11
Russian (8) 8
Italian (7) 7
Portuguese (3) 3
Polish (2) 2
Swedish (2) 2
Danish (1) 1
Dutch (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes
by Ménochet, Karelle and Kenworthy, Kathryn E and Houston, J. Brian and Galetin, Aleksandra
Drug Metabolism and Disposition, ISSN 0090-9556, 09/2012, Volume 40, Issue 9, pp. 1744 - 1756
Interindividual variability in activity of uptake transporters is evident in vivo, yet limited data exist in vitro, confounding in vitro-in vivo extrapolation.... 
DRUG TRANSPORTERS | IN-VITRO CLEARANCE | CRYOPRESERVED HUMAN HEPATOCYTES | HMG-COA REDUCTASE | PHARMACOLOGY & PHARMACY | ANION TRANSPORTING POLYPEPTIDES | HEPATIC-UPTAKE | HEALTHY-VOLUNTEERS | METABOLIC ENZYMES | RECEPTOR ANTAGONIST | PREDICTION | Antihypertensive Agents - pharmacology | Tetrazoles - pharmacology | Species Specificity | Valsartan | Hypoglycemic Agents - metabolism | Benzoates - metabolism | Humans | Antihypertensive Agents - metabolism | Hepatocytes - metabolism | Angiotensin II Type 1 Receptor Blockers - pharmacology | Angiotensin II Type 1 Receptor Blockers - metabolism | Organic Anion Transporters - metabolism | Pyrimidines - metabolism | Quinolines - pharmacology | Tetrazoles - metabolism | Carbamates - metabolism | Dose-Response Relationship, Drug | Fluorobenzenes - pharmacology | Drug Interactions | Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism | Biological Transport | Piperidines - pharmacology | Hepatocytes - drug effects | Carbamates - pharmacology | Pravastatin - pharmacology | Fluorobenzenes - metabolism | Piperidines - metabolism | Pravastatin - metabolism | Valine - analogs & derivatives | Rats | Rosuvastatin Calcium | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Hypoglycemic Agents - pharmacology | Quinolines - metabolism | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Valine - metabolism | Models, Biological | Benzimidazoles - metabolism | Sulfonamides - metabolism | Benzoates - pharmacology | Benzimidazoles - pharmacology | Kinetics | Valine - pharmacology | Organic Anion Transporters - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3
by Johannes Noà and Renée Portmann and Marie-Elise Brun and Christoph Funk
Drug Metabolism and Disposition, ISSN 0090-9556, 08/2007, Volume 35, Issue 8, pp. 1308 - 1314
Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute carriers are more and more recognized as being involved in hepatic... 
RAT | SEVERE RHABDOMYOLYSIS | COMBINATION THERAPY | LIVER | PHARMACOLOGY & PHARMACY | CERIVASTATIN | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | ROSUVASTATIN | POLYPEPTIDE | FAMILY | Organic Anion Transporters, Sodium-Independent - genetics | Fatty Acids, Monounsaturated - pharmacology | Cricetulus | Hypolipidemic Agents - metabolism | Hypoglycemic Agents - metabolism | Taurocholic Acid - metabolism | Humans | Hepatocytes - metabolism | Simvastatin - pharmacology | Organic Anion Transporters - metabolism | Chromans - metabolism | Hepatocytes - cytology | Indoles - metabolism | Organic Anion Transporters - genetics | Drug Interactions | Anticholesteremic Agents - metabolism | Chromans - pharmacology | Fatty Acids, Monounsaturated - metabolism | Organic Anion Transporters, Sodium-Independent - metabolism | Indoles - pharmacology | Biological Transport - drug effects | Thiazolidinediones - pharmacology | Hepatocytes - drug effects | Solute Carrier Organic Anion Transporter Family Member 1B3 | CHO Cells | Pravastatin - pharmacology | Recombinant Proteins - metabolism | Taurocholic Acid - pharmacology | Cell Line | Cricetinae | Pravastatin - metabolism | Simvastatin - metabolism | Gemfibrozil - pharmacokinetics | Gemfibrozil - pharmacology | Hypolipidemic Agents - pharmacology | Thiazolidinediones - metabolism | Hypoglycemic Agents - pharmacology | Animals | Estrone - analogs & derivatives | Estrone - metabolism | Protein Binding | Fatty Acids, Monounsaturated - pharmacokinetics | Indoles - pharmacokinetics | Kinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Anticholesteremic Agents - pharmacology | Gemfibrozil - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effect of quercetin on the uptake and efflux of aristolochic acid I from Caco‐2 cell monolayers
by Kimura, Osamu and Fujii, Yukiko and Haraguchi, Koichi and Ohta, Chiho and Koga, Nobuyuki and Kato, Yoshihisa and Endo, Tetsuya
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 07/2016, Volume 68, Issue 7, pp. 883 - 889
ObjectiveThe purpose of this study was to determine whether quercetin decreases the uptake of aristolochic acid I (AAI) from the apical membranes of Caco-2... 
Aristolochic acid I | Caco‐2 cell | monocarboxylic acid transporters | quercetin | breast cancer resistance protein | Monocarboxylic acid transporters | Breast cancer resistance protein | Caco-2 cell | Quercetin | BCRP | MONOCARBOXYLATE TRANSPORTERS | FLAVONOIDS | TRANSCELLULAR TRANSPORT | NEPHROPATHY | P-GLYCOPROTEIN | FAMILY | PHARMACOLOGY & PHARMACY | ABC TRANSPORTERS | EXPRESSION | CANCER RESISTANCE PROTEIN | Caco-2 Cells | Pravastatin - pharmacology | Propionates - pharmacology | Cyclosporine - pharmacology | Benzoic Acid - pharmacology | Humans | Cells, Cultured | Intestinal Absorption - drug effects | Acetic Acid - pharmacology | Quinidine - pharmacology | Diketopiperazines - pharmacology | Heterocyclic Compounds, 4 or More Rings - pharmacology | Indomethacin - pharmacology | Quinolines - pharmacology | Aristolochic Acids - pharmacokinetics | Quercetin - pharmacology | Biological Transport - drug effects | Mitoxantrone - pharmacology | ATP-Binding Cassette Transporters - antagonists & inhibitors | Hydrogen-Ion Concentration | Benzoic acid | Organic acids | Monomolecular films | Acids | Ions | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction
by Lau, Wei C and Waskell, Lucy A and Watkins, Paul B and Neer, Charlene J and Horowitz, Kevin and Hopp, Amy S and Tait, Alan R and Carville, David G.M and Guyer, Kirk E and Bates, Eric R
Circulation, ISSN 0009-7322, 01/2003, Volume 107, Issue 1, pp. 32 - 37
Background-We observed that the prodrug clopidogrel was less effective in inhibiting platelet aggregation with coadministration of atorvastatin during... 
Drugs | Pharmacology | Platelets | Statins | CLINICAL-PHARMACOLOGY | ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | REDUCTASE INHIBITOR | EVENTS | drugs | ASPIRIN | platelets | ANTIAGGREGATING ACTIVITY | THERAPY | TICLOPIDINE | statins | pharmacology | PERIPHERAL VASCULAR DISEASE | SIMVASTATIN | ACTIVE METABOLITE | Pravastatin - pharmacology | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 CYP3A | Erythromycin - pharmacology | Humans | Breath Tests | Enzyme Inhibitors - pharmacology | Ticlopidine - antagonists & inhibitors | Male | Ticlopidine - analogs & derivatives | Dose-Response Relationship, Drug | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Adolescent | Atorvastatin | Platelet Aggregation Inhibitors - pharmacology | Adult | Clopidogrel | Female | Platelet Aggregation - drug effects | Heptanoic Acids - pharmacology | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies
by Variya, Bhavesh C and Patel, Snehal S and Trivedi, Jinal I and Gandhi, Hardik P and Rathod, S.P
European Journal of Pharmacology, ISSN 0014-2999, 10/2015, Volume 764, pp. 283 - 291
The present study was carried out to evaluate the protective effect of different statins on isoproterenol (ISO) induced myocardial necrosis. Atorvastatin,... 
Fluvastatin | Simvastatin | Atorvastatin | Rosuvastatin | Myocardial necrosis | Isoproterenol | Pravastatin | CHRONIC HEART-FAILURE | COENZYME-A REDUCTASE | CHOLESTEROL | INFARCTION | PLASMA | PHARMACOLOGY & PHARMACY | RAT-HEART | LIPOPROTEINS | STATIN TREATMENT | Necrosis - drug therapy | Myocardial Infarction - chemically induced | Simvastatin - therapeutic use | Fatty Acids, Monounsaturated - pharmacology | Rosuvastatin Calcium - therapeutic use | Rats, Wistar | Atorvastatin Calcium - pharmacology | Glutathione - metabolism | Cholesterol - blood | Male | Simvastatin - pharmacology | Necrosis - pathology | Cardiotonic Agents - therapeutic use | Fatty Acids, Monounsaturated - therapeutic use | Myocardial Infarction - pathology | Myocardium - metabolism | Indoles - pharmacology | Pravastatin - therapeutic use | Atorvastatin Calcium - therapeutic use | Superoxide Dismutase - metabolism | Pravastatin - pharmacology | Blood Glucose - analysis | Rosuvastatin Calcium - pharmacology | Adenosine Triphosphatases - metabolism | Myocardium - pathology | Necrosis - metabolism | Cardiotonic Agents - pharmacology | Myocardial Infarction - metabolism | Necrosis - chemically induced | Catalase - metabolism | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Myocardial Infarction - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Isoproterenol - pharmacology | Triglycerides - blood | Indoles - therapeutic use | Isoproterenol - therapeutic use | Antioxidants | Pharmacy | Drugstores | Glucose | Comparative analysis | Statins | Dextrose | Necrosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Oxidative Stress and Inflammation Are Differentially Affected by Atorvastatin, Pravastatin, Rosuvastatin, and Simvastatin on Lungs from Mice Exposed to Cigarette Smoke
by Ferreira, Thiago Santos and Lanzetti, Manuella and Barroso, Marina Valente and Rueff-Barroso, Carlos Romualdo and Benjamim, Cláudia Farias and de Brito-Gitirana, Lycia and Porto, Luís Cristóvão and Valença, Samuel Santos
Inflammation, ISSN 0360-3997, 10/2014, Volume 37, Issue 5, pp. 1355 - 1365
Our aim was to investigate the effects of four different statins on acute lung inflammation induced by cigarette smoke (CS). C57BL/6 male mice were divided... 
lung | Pathology | Medicine & Public Health | inflammation | statins | Rheumatology | Internal Medicine | Pharmacology/Toxicology | cigarette smoke | mice | oxidative stress | NADPH OXIDASE | COA REDUCTASE INHIBITORS | LIPID-PEROXIDATION | INJURY | DEFICIENT MICE | INOS | IMMUNOLOGY | HUMAN MONOCYTES | CELL BIOLOGY | LEUKOTRIENE B-4 | NITRIC-OXIDE | INDUCED PULMONARY-HYPERTENSION | Simvastatin - therapeutic use | Heptanoic Acids - therapeutic use | Oxidative Stress - physiology | Male | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Inflammation Mediators - metabolism | Anti-Inflammatory Agents - therapeutic use | Inhalation Exposure - adverse effects | Inflammation Mediators - antagonists & inhibitors | Lung - metabolism | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Lung - pathology | Anti-Inflammatory Agents - pharmacology | Mice, Inbred C57BL | Smoking - drug therapy | Rosuvastatin Calcium | Antioxidants - pharmacology | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Atorvastatin Calcium | Smoking - metabolism | Antioxidants - therapeutic use | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Lung - drug effects | Smoking - pathology | Mice | Oxidative Stress - drug effects | Fluorobenzenes - therapeutic use | Oxidative stress | Complications and side effects | Inflammation | Research | Cigarette smoke | Risk factors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Statins as a newly recognized type of immunomodulator
by Myit, Samir and Mach, François and Kwak, Brenda and Mulhaupt, Flore
Nature Medicine, ISSN 1078-8956, 12/2000, Volume 6, Issue 12, pp. 1399 - 1402
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or statins, are effective lipid-lowering agents, extensively used in medical... 
MEDICINE, RESEARCH & EXPERIMENTAL | CIITA | CHOLESTEROL | BIOCHEMISTRY & MOLECULAR BIOLOGY | GENES | CLASS-II TRANSACTIVATOR | EXPRESSION | DEFICIENCY | CELL BIOLOGY | Endothelium, Vascular - cytology | Pravastatin - pharmacology | Genes, MHC Class II | Adjuvants, Immunologic - pharmacology | Lovastatin - pharmacology | T-Lymphocytes | Lymphocyte Activation | Monocytes - cytology | Humans | Macrophages - cytology | Nuclear Proteins | Atorvastatin Calcium | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Trans-Activators - genetics | Saphenous Vein - cytology | Anticholesteremic Agents - pharmacology | Heptanoic Acids - pharmacology | Interferon-gamma - pharmacology | Usage | Clinical trials | Management | Research | Drug therapy | Coronary heart disease | Health aspects | Statins | g-Interferon | statins | 3-hydroxy-3-methylglutaryl CoA reductase | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study
by Park, Yongwhi and Jeong, Young-Hoon and Tantry, Udaya S and Ahn, Jong Hwa and Kwon, Tae Jung and Park, Jeong Rang and Hwang, Seok-Jae and Gho, Eun-Ha and Bliden, Kevin P and Kwak, Choong Hwan and Hwang, Jin-Yong and Kim, Sunjoo and Gurbel, Paul A
European Heart Journal, ISSN 0195-668X, 09/2012, Volume 33, Issue 17, pp. 2151 - 2162
Aims CYP3A4-metabolized statins can influence the pharmacodynamic effect of clopidogrel. We sought to assess the impact of switching to a... 
Atorvastatin | Clopidogrel | Platelet | Non-CYP3A4-metabolized statin | High platelet reactivity | REDUCTASE INHIBITORS | CARDIAC & CARDIOVASCULAR SYSTEMS | ABCB1 | GENETIC-VARIANTS | CYP2C19 | CYTOCHROME-P450 3A4 | CLINICAL PHARMACOGENETICS | DRUG-DRUG INTERACTION | TRIAL | PERCUTANEOUS CORONARY INTERVENTION | Prospective Studies | Ticlopidine - therapeutic use | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Cytochrome P-450 CYP3A - physiology | Male | Pyrimidines - metabolism | Fluorobenzenes - pharmacology | Cytochrome P-450 CYP3A - genetics | Platelet Aggregation Inhibitors - pharmacology | Female | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Fluorobenzenes - metabolism | Pravastatin - metabolism | Rosuvastatin Calcium | Genotype | Coronary Artery Disease - drug therapy | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Ticlopidine - analogs & derivatives | Adenosine Diphosphate - pharmacology | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Sulfonamides - metabolism | Drug Substitution | Fluorobenzenes - therapeutic use | Percutaneous Coronary Intervention | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Statins Inhibit Proliferation and Induce Apoptosis in Barrett's Esophageal Adenocarcinoma Cells
by Ogunwobi, Olorunseun O and Beales, Ian L. P
The American Journal of Gastroenterology, ISSN 0002-9270, 04/2008, Volume 103, Issue 4, pp. 825 - 837
OBJECTIVES: The incidence and mortality rates from esophageal adenocarcinoma (EAC) are rapidly increasing in the western world. Chemoprevention is being... 
LOVASTATIN | COLON-CANCER CELLS | INCREASES PROLIFERATION | ACTIVATION | A-REDUCTASE INHIBITORS | PANCREATIC-CANCER | GROWTH | MEVALONATE PATHWAY | GASTROENTEROLOGY & HEPATOLOGY | PHASE-I | STIMULATES PROLIFERATION | Adenocarcinoma - pathology | Lovastatin - pharmacology | Apoptosis - drug effects | Esophageal Neoplasms - prevention & control | RNA, Messenger - analysis | Immunoblotting | Nitrobenzenes - pharmacology | Simvastatin - pharmacology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Barrett Esophagus - pathology | Caspase 3 - drug effects | Mevalonic Acid - pharmacology | Pravastatin - pharmacology | Barrett Esophagus - metabolism | Protein Kinases - drug effects | Reverse Transcriptase Polymerase Chain Reaction | Sulfonamides - pharmacology | Cell Division - drug effects | Adenocarcinoma - prevention & control | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Analysis of Variance | Signal Transduction - drug effects | Cell Line, Tumor | Polyisoprenyl Phosphates - pharmacology | Sesquiterpenes - pharmacology | Adenocarcinoma | Hypercholesterolemia | Esophageal cancer | Statins | Cardiovascular agents | Apoptosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis
by Lu, Yongbin and Cheng, Zhiyuan and Zhao, Yaxue and Chang, Xiaoyu and Chan, Cynthia and Bai, Yana and Cheng, Ning
Atherosclerosis, ISSN 0021-9150, 2016, Volume 254, pp. 215 - 227
Abstract Background and aims Our study aims to evaluate the efficacy and safety of long-term treatment of statins for coronary heart disease (CHD). Methods... 
Cardiovascular | Efficacy | Statin | Safety | Mortality | CHD | Blood-lipid | CARDIAC & CARDIOVASCULAR SYSTEMS | HIGH-DOSE ATORVASTATIN | INFECTION THERAPY | CARDIOVASCULAR EVENTS | LOW-DENSITY-LIPOPROTEIN | SCANDINAVIAN SIMVASTATIN SURVIVAL | LIPID-LOWERING THERAPY | SECONDARY PREVENTION | RENAL-TRANSPLANT RECIPIENTS | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | AVERAGE CHOLESTEROL LEVELS | Pravastatin - pharmacology | Fatty Acids, Monounsaturated - pharmacology | Lovastatin - pharmacology | Atorvastatin Calcium - pharmacology | Humans | Kidney Diseases - drug therapy | Treatment Outcome | Lovastatin - analogs & derivatives | Simvastatin - pharmacology | Quinolines - pharmacology | Randomized Controlled Trials as Topic | Coronary Disease - pathology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Lipids - blood | Muscles - drug effects | Bayes Theorem | Patient Safety | Coronary Disease - drug therapy | Indoles - pharmacology | Network Meta-Analysis | Anticholesteremic Agents - pharmacology | Epidemiology | Coronary heart disease | Analysis | Statins | Cardiovascular agents | Blood lipids | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The Influence of Statin Medications on Prostate-specific Antigen Levels
by Hamilton, Robert J and Goldberg, Kenneth C and Platz, Elizabeth A and Freedland, Stephen J
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2008, Volume 100, Issue 21, pp. 1511 - 1518
Background Recent data suggest that statin use may be associated with a reduced risk of advanced prostate cancer. However, the influence of statins on... 
REDUCTASE INHIBITORS | COA REDUCTASE | UNITED-STATES | POPULATION | METAANALYSIS | ONCOLOGY | COLORECTAL-CANCER | CHOLESTEROL-LOWERING DRUGS | MEN | CANCER-RISK | COHORT | Multivariate Analysis | Fatty Acids, Monounsaturated - pharmacology | Lovastatin - pharmacology | Humans | Middle Aged | Male | Prostatic Neoplasms - diagnosis | Simvastatin - pharmacology | Incidence | Prostatic Neoplasms - immunology | Prostate-Specific Antigen - drug effects | Cholesterol, LDL - blood | Indoles - pharmacology | Prostatic Neoplasms - prevention & control | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Risk Assessment | Linear Models | Prostate-Specific Antigen - blood | Biomarkers, Tumor - blood | Atorvastatin Calcium | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cholesterol, HDL - blood | Aged | Veterans - statistics & numerical data | Early Diagnosis | Longitudinal Studies | Measurement | Prostate-specific antigen | Dosage and administration | Diagnosis | Drug therapy | Prostate cancer | Health aspects | Statins | Mens health | Side effects | Blood tests | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights